<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675959</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC 571</org_study_id>
    <secondary_id>4090</secondary_id>
    <nct_id>NCT02675959</nct_id>
  </id_info>
  <brief_title>Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease</brief_title>
  <acronym>NYMC-571</acronym>
  <official_title>Safety and Efficacy of Prophylactic Defibrotide in Children, Adolescents, and Young Adults With Sickle Cell Disease or Beta Thalassemia Following MAC and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and&#xD;
      toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta&#xD;
      thalassemia patients undergoing a familial haploidentical allogeneic stem cell&#xD;
      transplantation with CD34 enrichment and T-cell addback. This patient population historically&#xD;
      has a risk of developing sinusoidal obstructive syndrome (SOS) and Defibrotide has&#xD;
      demonstrated efficacy in treatment of SOS. The Funding Source is FDA OOPD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All patients will be monitored for known and unknown side effects of defibrotide with daily physical exams while in the hospital and then as needed in addition to daily laboratory values including chemistries, hematology labs as needed</measure>
    <time_frame>100 days</time_frame>
    <description>Patients will be given Defibrotide prophylaxis starting 10 days before the stem cell infusion at 6.25 mg/kg IV q6h and continue through Day +21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All patients will be monitored for the development of SOS.</measure>
    <time_frame>1 year</time_frame>
    <description>All patients will get daily lab values while in patients and then as needed to monitor for elevation in liver function tests and other abnormal chemistry or hematology values. Imaging on the liver will be performed as needed to determine if they develop SOS with defibrotide.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Defibrotide prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>defibrotide will be given prior to and during myeloablative immunotherapy conditioning (MAIC) followed by familial haploidentical (FHI) allogeneic stem cell transplantation (AlloSCT) with CD34 enrichment and t-cell addback in patients with high-risk sickle cell disease or beta thalassemia to reduced the risk and rate of the development of sinusoidal obstructive syndrome (SOS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Defibrotide</intervention_name>
    <description>defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.</description>
    <arm_group_label>Defibrotide prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease: Homozygous Hemoglobin S Disease, or Hemoglobin S B0/+ thalassemia, or&#xD;
             Hemoglobin SC Disease, or Beta thalassemia intermedia/majora&#xD;
&#xD;
          -  Patients must demonstrate one or more of the following Sickle Cell Disease&#xD;
             Complications (or patients in Cohort 2 can meet other high risk criteria instead)&#xD;
&#xD;
          -  Clinically significant neurologic event (stroke) or any neurologic deficit lasting &gt;24&#xD;
             hours that is accompanied by an infarct on cerebral MRI&#xD;
&#xD;
          -  Acute chest syndrome in the preceding two year period prior to enrollment that have&#xD;
             failed, been non-compliant or declined hydroxyurea treatment, or prior to chronic RBC&#xD;
             transfusion therapy, exchange transfusion or erythrocyte pheresis.&#xD;
&#xD;
          -  Recurrent painful events (at least 3 in the 2 years prior to enrollment or prior to&#xD;
             chronic chronic RBC transfusion therapy, exchange transfusion or erythrocyte&#xD;
             pheresis).&#xD;
&#xD;
          -  Abnormal TCD study requiring starting on chronic transfusion therapy and/or exchange&#xD;
             transfusions.&#xD;
&#xD;
          -  At least one silent infarct lesion on a MRI scan of the head. Or (directly or probably&#xD;
             related to SCD)&#xD;
&#xD;
          -  Sickle Cell nephropathy;&#xD;
&#xD;
          -  Splenic sequestration requiring RBC transfusion;&#xD;
&#xD;
          -  Aplastic crisis requiring RBC transfusion;&#xD;
&#xD;
          -  Avascular necrosis of the hip diagnosed by MRI;&#xD;
&#xD;
          -  Two episodes or more of leg ulcerations;&#xD;
&#xD;
          -  Recurrent priapism .&#xD;
&#xD;
          -  Infant dactylitis.&#xD;
&#xD;
               -  OR for Cohort #2 ONLY: Patient must be between 18 and 34.99 years of age,&#xD;
                  patients must demonstrate at least two of the following:&#xD;
&#xD;
          -  WBC &gt; 13,500 cells/microliter at baseline when not acutely ill (on two separate&#xD;
             occasions) &gt; 2 weeks from a VOC event or hospitalization.&#xD;
&#xD;
          -  Tricuspid Regurgitant Jet Velocity (TRV) &gt; 3.0 m/s&#xD;
&#xD;
          -  Requiring Chronic Monthly Transfusions ( &gt; 12 transfusions in the 12 months)&#xD;
&#xD;
          -  History of sepsis&#xD;
&#xD;
          -  N-terminal pro-brain natriuretic peptide (NT-proBNP) &gt; 160 ng/L at clinical baseline&#xD;
             when not acutely ill or hospitalized.&#xD;
&#xD;
          -  all patients must meet disease, age, organ function and donor criteria;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are receiving concomitant systemic anticoagulants and/or fibrinolytic&#xD;
             therapies.&#xD;
&#xD;
          -  Patients with a previously known hypersensitivity reaction to defibrotide.&#xD;
&#xD;
          -  Females who are pregnant or breast-feeding are not eligible&#xD;
&#xD;
          -  SCD Patients with documented uncontrolled infection at the time of study entry are not&#xD;
             eligible.&#xD;
&#xD;
          -  SCD patients who have an unaffected HLA matched family donor willing to proceed to&#xD;
             donation will not be eligible for this study.&#xD;
&#xD;
          -  Karnofsky or Lansky (age appropriate) Performance Score &lt;50% (hemiplegia alone&#xD;
             secondary to a previous stroke is not an exclusion)&#xD;
&#xD;
          -  Demonstrated lack of compliance with medical care.&#xD;
&#xD;
          -  Patients with clinically significant fibrosis or cirrhosis of the liver will not be&#xD;
             eligible.&#xD;
&#xD;
          -  Patients who have previously received a HSCT will not be eligible.&#xD;
&#xD;
          -  Patients with contraindications to the use of defibrotide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Cairo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitchell S Cairo, MD</last_name>
    <phone>914-594-2150</phone>
    <email>Mitchell_Cairo@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Morris, RN</last_name>
    <phone>714-964-5359</phone>
    <email>erin_morris@nymc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore B Moore, MD</last_name>
      <phone>310-825-6708</phone>
      <email>tbmoore@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andres Vargas</last_name>
      <phone>310-794-8929</phone>
      <email>AndresVargas@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Theodore B Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-1274</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghada Abusin, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Bre'Anna Simpson</last_name>
      <email>sbreanna@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ghada Abusin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Fabricatore, RN, PNP</last_name>
      <phone>914-594-2152</phone>
      <email>sandra.fabricatore@wmchealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Erin Morris, RN</last_name>
      <phone>714-964-5359</phone>
      <email>erin_morris@nymc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mitchell S Cairo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie A Talano, MD</last_name>
      <phone>414-955-4185</phone>
      <email>jtalano@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Ruszkiewicz</last_name>
      <email>eruszkiewicz@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Julie A Talano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Mitchell Cairo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stem cell transplantation</keyword>
  <keyword>sickle cell disease</keyword>
  <keyword>haploidentical</keyword>
  <keyword>defibrotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Defibrotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

